Cargando…
Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
OBJECTIVE: The TOPAZ-1 trial reported a significant survival benefit of durvalumab in combination with chemotherapy for the first-line treatment of biliary tract cancer (BTC). However, no studies have evaluated the economics of this treatment option. The aim of this study was to assess the cost effe...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950513/ https://www.ncbi.nlm.nih.gov/pubmed/36844853 http://dx.doi.org/10.3389/fpubh.2023.1046424 |